top of page
Doctor Using Digital Tablet_edited.jpg

ABOUT US

Curespec is ushering in a new era of hope for chronic kidney disease (CKD) and hypertensive patients with Nephrospec™, our cutting-edge technology.

We stand as pioneers, offering a life-extending treatment that revitalizes kidneys, delays the need for dialysis, and lowers blood pressure, all while making significant cost savings for healthcare systems.

Nephrospec™ is a safe, non-invasive low intensity electro-Hydraulic Acoustic Therapy (eHAT) device for the treatment of CKD and hypertension. 

Our patented technology promotes new blood vessel formation and restores damaged tissue function while saving up to 80% of the costs associated with dialysis.

 

Nephrospec™ by Curespec:

A complementary solution to optimize medical care for CKD and     hypertension

Improvement of kidney function within a few weeks 

Delayed onset of outpatient treatment for dialysis

Nephrospec- curespec logo_edited_edited_edited.jpg

OUR PRODUCT

Pre treatment

ARAS Kidney

Post Nephrospec™ treatment

Curespec uses electro-Hydro Acoustic Therapy to produce a neovascularization effect on the kidneys

CLINICAL APPLICATIONS

Low–Energy Shockwave Therapy Improves Ischemic Kidney Microcirculation

Zhang X, Krier JD, Carrascal CA, et al.

J Am Soc Nephrol. 2016; 27(12):3715-3724. 

Low-Energy Shockwave Treatment Promotes Endothelial Progenitor Cell Homing to the Stenotic Pig Kidney

Zhao Y, Santelli A, Zhu XY, et al.

Cell Transplant. 2020; 29.

It Comes As a Shock

Kidney Repair Using Shockwave Therapy

Klomjit N, Lerman A, Lerman LO.

Hypertension. Published online 2020:1696-1703. 

Magnetic resonance elastography can monitor changes in medullary  stiffness in response to treatment in the swine ischemic kidney

Zhang X, Zhu X, Ferguson CM, et al.

Magn Reson Mater Physics, Biol Med. 2018; 31(3):375-382.

Adjunctive mesenchymal stem / stromal cells augment microvascular function in poststenotic kidneys treated with low-energy shockwave therapy

Chen X-J, Zhang X, Jiang K, et al

J Cell Physiol. 2020; 235(12):9806-9818. 

Innovation in Cardiovascular Interventions Meeting:
First results using a new renal restoration approach to treat hypertension and preserve renal function in CKD patients -
Presented by Prof. Talya Wolak

Our Team

Our Team

Avner Spector_edited.jpg

Avner Spector

Founder, Active Chairman

Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies. 

  • Grey LinkedIn Icon
rotem k_edited.jpg

Rotem Kaynan

CEO

Mr. Kaynan is a Biomedical Engineer. More than 20 years of experience in Medical Devices, leading teams of clinical applications, sales & product management.

  • Grey LinkedIn Icon
Sandra_Morgan_Potrero_Medical.jpg

Sandra Morgan

Executive Advisor

Ms.  Morgan has over  32 years in healthcare with Fortune 100 companies including HCA Healthcare and Pfizer. In the past she was an executive at HCA Healthcare responsible for business growth through physicians and service lines. In her last role at Pfizer, Sandra led the US managed care team responsible for achieving formulary status for Pfizer’s portfolio.

  • Grey LinkedIn Icon

Advisory Board

Lilach%20Lerman_edited.jpg

Lilach O. Lerman, MD, PhD

The Arthur M. and Gladys D. Gray Professor in Honor of Dr. Howard A. Andersen Professor of Medicine and Physiology Director, Reno- Vascular Research Laboratory Division of Nephrology and Hypertension Mayo Clinic

Amir%20Lerman%2C%20M.D._edited.jpg

Amir Lerman, M.D.

Barbara Woodward Lips Professor 

Associate Chair, Cardiovascular  Medicine Director - Cardiovascular Research Center Consultant, Department of Cardiovascular Medicine Mayo Clinic

Contact Us

203 Perry Pkwy, Suite # 6 Gaithersburg, MD 20877-2169, USA

Office 301.944.1575

Thanks for submitting!

  • Instagram
  • Facebook
  • LinkedIn

Contact Us

bottom of page